Database Query Results : , , hTERT/TERT

hTERT/TERT, human telomerase reverse transcriptase: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
A key component of the enzyme telomerase, which is responsible for maintaining the length of telomeres at the ends of chromosomes.
In most somatic cells, telomerase activity is low or absent, leading to progressive telomere shortening with each cell division, which eventually triggers cellular senescence or apoptosis. many cancer cells exhibit reactivation of telomerase, primarily through the upregulation of hTERT. This reactivation allows cancer cells to maintain their telomere length, enabling them to divide indefinitely and contributing to the immortality characteristic of cancer cells. The expression of hTERT is often associated with various types of cancer, including melanoma, breast cancer, and lung cancer.
| Cancer context | TERT biomarker                | Clinical use                             |
| -------------- | ----------------------------- | ---------------------------------------- |
| Glioma         | Promoter mutation             | **WHO classification, prognosis**        |
| Thyroid cancer | Promoter mutation             | **Aggressiveness, recurrence risk**      |
| Melanoma       | Promoter mutation             | Risk stratification                      |
| Bladder cancer | Promoter mutation (urine DNA) | **Noninvasive detection & surveillance** |
| HCC            | Promoter mutation             | Early event, prognosis                   |

Why TERT Is Valuable Despite Limited “Actionability”
-Telomere maintenance is mandatory for long-term tumor survival
-TERT activation is often an early, irreversible event
-Its presence signals a tumor that has escaped replicative limits
-That makes TERT one of the best markers of “point-of-no-return” biology.


Scientific Papers found: Click to Expand⟱
3435- aLinA,    Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa - in-vitro, Cerv, C33A
DNMTs↓, HDAC↓, HATs↑, hTERT/TERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,
2783- CHr,    Apoptotic Effects of Chrysin in Human Cancer Cell Lines
- Review, Var, NA
TumCP↓, Apoptosis↑, Casp↑, PCNA↓, p38↑, NF-kB↑, DNAdam↑, XIAP↓, Cyt‑c↑, Casp3↑, Akt↓, SCF↓, hTERT/TERT↓, COX2↓, *Inflam↓, *antiOx↑, *chemoPv↑, AR-V7?, CYP19?,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1/CCND1↓, hTERT/TERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
2790- CHr,    Chrysin: Pharmacological and therapeutic properties
- Review, Var, NA
*hepatoP↑, *neuroP↓, *ROS↓, *cardioP↑, *Inflam↓, eff↑, hTERT/TERT↓, cycD1/CCND1↓, MMP9↓, MMP2↓, TIMP1↑, TIMP2↑, BioAv↑, HK2↓, ROS↑, MMP↓, Casp3↑, ADP:ATP↑, Apoptosis↑, ER Stress↑, UPR↑, GRP78/BiP↝, eff↑, Ca+2↑,
2978- CUR,    N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells
- in-vitro, Lung, A549
ROS↑, hTERT/TERT↓, Sp1/3/4↓, eff↓,
668- EGCG,    The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment
- Review, BC, MCF-7 - Review, BC, MDA-MB-231
HER2/EBBR2↓, EGFR↓, mtDam↑, ROS↑, PI3K/Akt↓, P53↑, P21↑, Casp3↑, Casp9↑, BAX↑, PTEN↑, Bcl-2↓, hTERT/TERT↓, STAT3↓, TumCCA↑, Hif1a↓,
3233- EGCG,    Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways
- in-vitro, Cerv, HeLa
DNMTs↓, DNMT1↓, DNMT3A↓, HDAC2↓, HDAC3↓, HDAC4↓, EZH2↓, PI3K↓, Wnt↓, MAPK↓, hTERT/TERT↓, MMP2↓, MMP7↓, IL6↓, MDM2↓, MMP-10↓, TP53↑, PTEN↑,
1435- GEN,  SFN,    The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
DNMTs↓, HDAC↓, eff↑, TumCCA↑, HMTs↓, HDAC2↓, HDAC3↓, KLF4↓, hTERT/TERT↓,
1504- GEN,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
DNMTs↓, P21↑, p16↑, ac‑H3↑, ac‑H4↑, TumCCA↑, Casp↑, Apoptosis↑, hTERT/TERT↓, BTG3↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2912- LT,    Luteolin: a flavonoid with a multifaceted anticancer potential
- Review, Var, NA
ROS↑, TumCCA↑, TumCP↓, angioG↓, ER Stress↑, mtDam↑, PERK↑, ATF4↑, eIF2α↑, cl‑Casp12↑, EMT↓, E-cadherin↑, N-cadherin↓, Vim↓, *neuroP↑, NF-kB↓, PI3K↓, Akt↑, XIAP↓, MMP↓, Ca+2↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Cyt‑c↑, IronCh↑, SOD↓, *ROS↓, *LDHA↑, *SOD↑, *GSH↑, *BioAv↓, Telomerase↓, cMyc↓, hTERT/TERT↓, DR5↑, Fas↑, FADD↑, BAD↑, BOK↑, BID↑, NAIP↓, Mcl-1↓, CDK2↓, CDK4↓, MAPK↓, AKT1↓, Akt2↓, *Beclin-1↓, Hif1a↓, LC3II↑, Beclin-1↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
1672- PBG,    The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers
- Review, BC, NA
ChemoSen↓, RadioS↑, Inflam↓, AntiCan↑, Dose∅, mtDam↑, Apoptosis?, OCR↓, ATP↓, ROS↑, ROS↑, LDH↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eNOS↑, iNOS↑, eff↑, hTERT/TERT↓, cycD1/CCND1↓, eff↑, eff↑, eff↑, eff↑, STAT3↓, TIMP1↓, IL4↓, IL10↓, OS↑, Dose∅, ER Stress↑, ROS↑, NF-kB↓, p65↓, MMP↓, TumAuto↑, LC3II↑, p62↓, TLR4↓, mtDam↑, LDH↓, ROS↑, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDH↓, IL10↓, HDAC8↓, eff↑, eff↑, P21↑,
1730- SFN,    Sulforaphane: An emergent anti-cancer stem cell agent
- Review, Var, NA
BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27↑, DNMT1↓, DNMT3A↓, cycD1/CCND1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT/TERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,
1502- SFN,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
HDAC↓, AntiCan↑, DNMTs↓, hTERT/TERT↓, selectivity↑,
1437- SFN,    Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition
- Review, NA, NA
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, eff↑, ac‑HSP90↑, DNMT1↓, DNMT3A↓, hTERT/TERT↓, NRF2↑, HO-1↑, NQO1↑, miR-155↓, miR-200c↑, SOX9↓, *toxicity↓,
1508- SFN,    Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment
- Review, Var, NA
*BioAv↑, HDAC↓, TumCCA↓, eff↓, Wnt↓, β-catenin/ZEB1↓, Casp12?, Bcl-2↓, cl‑PARP↑, Bax:Bcl2↑, IAP1↓, Casp3↑, Casp9↑, Telomerase↓, hTERT/TERT↓, ROS?, DNMTs↓, angioG↓, VEGF↓, Hif1a↓, cMYB↓, MMP1↓, MMP2↓, MMP9↓, ERK↑, E-cadherin↑, CD44↓, MMP2↓, eff↑, IL2↑, IFN-γ↑, IL1β↓, IL6↓, TNF-α↓, NF-kB↓, ERK↓, NRF2↑, RadioS↑, ChemoSideEff↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
382- SNP,    Investigation the apoptotic effect of silver nanoparticles (Ag-NPs) on MDA-MB 231 breast cancer epithelial cells via signaling pathways
- in-vitro, BC, MDA-MB-231
Apoptosis↑, BAX↑, Bcl-2↓, P53↑, PTEN↑, hTERT/TERT↓, p‑ERK↓, cycD1/CCND1↓,
2097- TQ,    Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells
- in-vitro, Cerv, HeLa
Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8↑, cl‑PARP↑, cMyc↓, hTERT/TERT↓, cycD1/CCND1↓, CDK4↓, P53↑, P21↑, TumCP↓, Apoptosis↓, selectivity↑,
2095- TQ,    Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis
- Review, Var, NA
TumCCA↑, Apoptosis↑, ROS↑, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, cl‑PARP↑, P53↑, P21↑, cMyc↓, hTERT/TERT↓, cycD1/CCND1↓, CDK4↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, COX2↓, MMP9↓, VEGF↓, eff↑,
1740- VitD3,    Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms
- Review, Var, NA
Risk↓, eff↑, eff↑, Risk↓, Risk↓, ChemoSen↑, RadioS↑, Cyt‑c↑, Casp3↑, Casp9↑, hTERT/TERT↓, eff↑, E-cadherin↑, CLDN2↑, ZO-1↑, Snail↓, Zeb1↓, Vim↓, VEGF↓, NK cell↑, Risk↓, eff↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 25

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Catalase↓, 1,   GSTA1↑, 1,   HO-1↓, 2,   HO-1↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   NQO1↑, 1,   NRF2↓, 4,   NRF2↑, 4,   ROS?, 1,   ROS↓, 2,   ROS↑, 19,   ROS⇅, 1,   SOD↓, 2,   Trx1↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   AIF↑, 1,   ATP↓, 1,   BOK↑, 1,   CDC2↓, 2,   MMP↓, 6,   MMP↑, 1,   mtDam↑, 4,   OCR↓, 1,   XIAP↓, 4,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   ALAT↓, 1,   cMyc↓, 3,   p‑cMyc↑, 1,   GlucoseCon↓, 2,   Glycolysis↓, 2,   HK2↓, 6,   lactateProd↓, 2,   LDH↓, 4,   LDL↓, 1,   PDK1↓, 1,   PFK↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 1,   PPARα↓, 1,   RARβ↑, 1,   SIRT1↓, 1,  

Cell Death ⓘ

Akt↓, 5,   Akt↑, 1,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↓, 1,   Apoptosis↑, 11,   BAD↑, 1,   BAX↓, 1,   BAX↑, 7,   Bax:Bcl2↑, 3,   Bcl-2↓, 5,   Bcl-xL↓, 2,   BID↑, 2,   BTG3↑, 1,   Casp↑, 2,   Casp12?, 1,   cl‑Casp12↑, 1,   Casp3↓, 1,   Casp3↑, 13,   cl‑Casp3↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 10,   cl‑Casp9↑, 1,   proCasp9↓, 1,   Cyt‑c↑, 9,   DR5↑, 3,   FADD↑, 1,   Fas↑, 1,   hTERT/TERT↓, 25,   IAP1↓, 2,   IAP2↓, 1,   iNOS↓, 2,   iNOS↑, 1,   JNK↑, 1,   MAPK↓, 3,   MAPK↑, 1,   Mcl-1↓, 2,   MDM2↓, 3,   NAIP↓, 1,   NICD↓, 1,   p27↑, 2,   p38↑, 1,   survivin↓, 3,   Telomerase↓, 3,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   SOX9↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 2,   ac‑H3↑, 1,   ac‑H4↑, 1,   HATs↑, 1,   miR-21↓, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 2,   p‑eIF2α↑, 1,   ER Stress↑, 6,   GRP78/BiP↑, 1,   GRP78/BiP↝, 1,   ac‑HSP90↑, 1,   PERK↑, 2,   UPR↑, 3,   XBP-1↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 2,   BNIP3↑, 1,   LC3B-II↑, 1,   LC3II↑, 2,   p62↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 5,   DNMT1↓, 5,   DNMT3A↓, 4,   DNMTs↓, 6,   p16↑, 1,   P53↑, 7,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 2,   TP53↓, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↑, 1,   CDK2↓, 6,   CDK4↓, 4,   cycA1/CCNA1↓, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 10,   cycD1/CCND1↑, 1,   P21↓, 1,   P21↑, 8,   TumCCA↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   ALDH1A1↓, 1,   AR-V7?, 1,   CD133↓, 1,   CD44↓, 2,   cMYB↓, 1,   CSCs↓, 1,   EMT↓, 7,   ERK↓, 4,   ERK↑, 1,   p‑ERK↓, 2,   p‑GSK‐3β↓, 1,   HDAC↓, 9,   HDAC1↓, 2,   HDAC2↓, 3,   HDAC3↓, 3,   HDAC4↓, 1,   HDAC8↓, 3,   HMTs↓, 1,   HMTs↑, 1,   KLF4↓, 1,   Let-7↑, 1,   mTOR↓, 1,   Nanog↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   NOTCH1↑, 2,   OCT4↓, 1,   PI3K↓, 5,   PTEN↑, 3,   RAS↓, 1,   SCF↓, 1,   SHP1↑, 1,   STAT3↓, 3,   p‑STAT3↓, 2,   p‑STAT3↑, 1,   STAT5↓, 1,   TAZ↓, 1,   TOP1↓, 1,   Wnt↓, 4,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AEG1↓, 1,   Akt2↓, 2,   AP-1↓, 1,   Ca+2↑, 6,   CDH1↑, 1,   CDKN1C↑, 1,   CLDN1↓, 2,   CLDN2↑, 1,   E-cadherin↑, 8,   FAK↓, 1,   Fibronectin↓, 1,   miR-155↓, 2,   miR-200c↑, 1,   MMP-10↓, 2,   MMP1↓, 1,   MMP2↓, 9,   MMP7↓, 1,   MMP9↓, 8,   MMPs↓, 1,   N-cadherin↓, 4,   Slug↓, 1,   Snail↓, 3,   TET1↑, 2,   TIMP1↓, 1,   TIMP1↑, 2,   TIMP2↑, 2,   TumCMig↓, 1,   TumCP↓, 7,   TumMeta↓, 1,   Twist↓, 4,   Vim↓, 4,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   ATF4↑, 2,   EGFR↓, 2,   p‑EGFR↓, 2,   eNOS↑, 1,   Hif1a↓, 5,   LOX1↓, 1,   NO↑, 1,   VEGF↓, 8,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   COX2↑, 2,   CXCR4↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   Igs↑, 1,   IL1↓, 1,   IL10↓, 3,   IL1β↓, 4,   IL2↑, 1,   IL4↓, 1,   IL6↓, 5,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 9,   NF-kB↑, 1,   p‑NF-kB↑, 1,   NK cell↑, 2,   p65↓, 1,   PGE2↓, 1,   TLR4↓, 2,   TNF-α↓, 4,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CYP19?, 1,   ER(estro)↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 4,   ChemoSen↓, 2,   ChemoSen↑, 7,   Dose?, 1,   Dose↝, 1,   Dose∅, 2,   eff↓, 3,   eff↑, 25,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 6,   selectivity↑, 5,   TET2↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 1,   EGFR↓, 2,   p‑EGFR↓, 2,   EZH2↓, 2,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 25,   IL6↓, 5,   LDH↓, 4,   TP53↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 2,   ChemoSideEff↓, 1,   neuroP↑, 2,   OS↑, 2,   RenoP↑, 1,   Risk↓, 4,   TumVol↓, 1,  
Total Targets: 283

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 2,   GSH↑, 1,   GSR↑, 1,   GSTs↑, 2,   HDL↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 5,   SOD↑, 3,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

LDHA↑, 1,   lipidLev↓, 1,  

Cell Death ⓘ

Akt↓, 1,   iNOS↓, 1,   MAPK↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,   HDAC3↓, 1,   PI3K↓, 1,   PTEN↑, 1,  

Migration ⓘ

Ki-67↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,   VEGF↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL2↓, 1,   Inflam↓, 3,   NF-kB↓, 2,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 6,   BioAv↑, 2,   P450↓, 1,  

Clinical Biomarkers ⓘ

AST↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   cognitive↑, 1,   hepatoP↑, 2,   neuroP↓, 1,   neuroP↑, 3,   RenoP↑, 1,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 47

Scientific Paper Hit Count for: hTERT/TERT, human telomerase reverse transcriptase
5 Chrysin
5 Sulforaphane (mainly Broccoli)
3 Luteolin
2 EGCG (Epigallocatechin Gallate)
2 Genistein (soy isoflavone)
2 Propolis -bee glue
2 Thymoquinone
1 alpha Linolenic acid
1 Curcumin
1 Silymarin (Milk Thistle) silibinin
1 Silver-NanoParticles
1 Vitamin D3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:150  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page